Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Overall experience with NovoSeven.

C Négrier1, A Lienhart

  • 1Centre de Traitement des Hemophiles, Laboratoire d'Hemostase, Hôpital Edouard Herriot, Lyon, France. negrier@laennec.univ-lyon1.fr

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|June 13, 2000
PubMed
Summary

Recombinant activated factor VII (rFVIIa) effectively treats bleeding in hemophilia patients with inhibitors. This therapy shows high efficacy and a good safety profile for various bleeding disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Onset of acquired haemophilia A after omalizumab treatment in severe bullous pemphigoid - a report on two cases successfully treated with mycophenolate mofetil.

Annales de dermatologie et de venereologie·2021
Same author

Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Recombinant activated factor VII in approved indications: Update on safety.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq<sup>®</sup> (human-cl rhFVIII) in previously treated patients with severe haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Postauthorization safety study of Clottafact<sup>®</sup> , a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study.

Vox sanguinis·2017
Same author

Comparison of an automated chemiluminescent assay to a manual ELISA assay for determination of von Willebrand Factor collagen binding activity on VWD plasma patients previously diagnosed through molecular analysis of VWF.

International journal of laboratory hematology·2017

Area of Science:

  • Hematology
  • Pharmacology

Background:

  • Recombinant activated factor VII (rFVIIa) was developed for hemophilia patients with inhibitors.
  • Conventional therapies are often ineffective for these patients.
  • rFVIIa has demonstrated safety and efficacy in clinical trials for home treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of rFVIIa in treating bleeding episodes.
  • To explore the potential use of rFVIIa in surgical procedures and other bleeding disorders.
  • To establish recommended dosing and administration guidelines for rFVIIa.

Main Methods:

  • Review of clinical trials and therapeutic outcomes.
  • Analysis of rFVIIa's mechanism of action and safety profile.
  • Examination of treatment effectiveness in congenital and acquired hemophilia.

Related Experiment Videos

Main Results:

  • rFVIIa is effective in up to 92% of congenital hemophilia cases.
  • It has a wide safety margin in acquired hemophilia, suggesting first-line therapy potential.
  • Dosing typically ranges from 60-120 microg/kg, with 90 microg/kg as a common initial dose.

Conclusions:

  • rFVIIa is a safe and effective treatment for hemophilia patients, including home therapy.
  • It is a valuable therapeutic option for acquired hemophilia and potentially other bleeding conditions.
  • Ongoing research suggests expanded indications for rFVIIa in platelet disorders and liver failure.